(11) Publication number:

**0 175 617** A3

**10** EUROPEAN PATENT APPLICATION

2) Application number: 85401776.1

(f) Int. Cl.4: A 61 K 39/395

2 Date of filing: 13.09.85

30 Priority: 13.09.84 US 650754 13.09.84 US 650375

- Date of publication of application: 26.03.86

  Bulletin 86/13
- Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE
- Date of deferred publication of search report: 15.06.88 Bulletin 88/24

- Applicant: CYTOGEN CORPORATION, 201 College Road East Forrestal Research Center, Princeton New Jersey 08540 (US)
- Inventor: Goers, John Waiter, 5200 Dolores Street,
  Atascadero California (US)
  Inventor: Lee, Chyl, 1347 Ute Road, New Brunswick New
  Jersey (US)
  Inventor: Siegel, Richard Charles, 117 Whiton Road,
  Neschanic Station New Jersey (US)
  Inventor: McKearn, Thomas Joseph, R.D. No. 3 Box 119,
  New Hope Pennsylvania (US)
  Inventor: King, Hurley Dalton, 1688-B Bluebird Drive,
  Yardley Pennsylvania (US)
  Inventor: Coughlin, Daniel James, 37-07 Hunters,
  Plainsboro New Jersey (US)
  Inventor: Rodwell, John Dennis, 430 Ramsey Road,
  Yardley Pennsylvania (US)
  Inventor: Alvarez, Vernon Leon, 187 Rice Drive,
  Morrisville Pennsylvania (US)
- (4) Representative: Warcoin, Jacques et al, Cabinet Régimbeau 26, avenue Kléber, F-75116 Paris (FR)
- 64 Antibody-therapeutic agent conjugates.
- This invention relates to antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therapeutic agent conjugates are described. Additionally novel photosensitizers suitable for use in preparing antibody-therapeutic agents are also described.

EP 0 175 617 A3



## PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

Application number EP 85 40 1776

		NSIDERED TO BE RELEVAN	11	
Category	of re	with indication, where appropriate, elevant passages	Relevant to claim	CLASSIFICATION OF TH APPLICATION (Int. CI.4)
		695 (CYTOGEN CORP.)		
	* Whole documen	t *	1-40,42	
	no. 3, March 19 American Associa Immunologists, D. MEW et al.: therapy: treatmoments with tumor-spectantibody-hemator	US; "Photoimmuno- ent of animal tumors ific monoclonal porphyrin conjugates		A 61 K 39/395
	* Whole document	t *	1-7,9- 15,17- 39,42	
Ţ	20th January 197 abstract no. 150 Columbus, Ohio, W.T. SHEARER et with antibody-gl conjugates speci	067u, US; al.: "Cytotoxicity		TECHNICAL FIELDS SEARCHED (Int. Cl.4)
INCOM	IPLETE SEARCH		-2-	A 61 K
out a mean Claims sea Claims not Reason for Iethoc animal	Search Division considers that the present European patent application does not comply with provisions of the European Patent Convention to such an extent that it is not possible to carry a meaningful search into the state of the art on the basis of some of the claims.  In searched completely: In searched incompletely: In searched: It is not possible to carry an extent that it is not possible to carry an extent of the claims.  In searched incompletely: In searched: It is not possible to carry an extent that it is not possible to carry an extent of the claims.  In searched incompletely: It is not possible to carry an extent that it is not possible to carry an extent of the claims.  In searched in the claims.  In searched in the claims.  It is not possible to carry an extent that it is not			
TH	Place of search IE HAGUE	Date of completion of the search 22-03-1988		Examiner SKELLY
X : parti	CATEGORY OF CITED DOCL cularly relevant if taken alone cularly relevant if combined w iment of the same category nological background written disclosure		nciple underlyi	ing the invention



	CLAIMS INCURRING FEES						
	•						
_							
The	The present European patent application comprised at the time of filing more than ten claims.						
l		All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.					
		Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid,					
		namely claims:					
1		No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.					
	<b></b>						
x	LA	CK OF UNITY OF INVENTION					
		Division considers that the present European patent application does not comply with the requirement of unity of					
nam		d relates to several inventions or groups of inventions,					
1	. c]	laims 1-40: Antibody-therapeutic agent conjugates					
		Laim 42: Novel compound					
		Laim 43: Novel compound					
_	. •						
:							
		-					
		<del>-</del>					
	X	All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.					
		Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid,					
		namely claims:					
		None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims,					
1		namely claims:					

## PARTIAL EUROPEAN SEARCH REPORT

0175617

EP 85 40 1776 -2-

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. CI 4)
ategory	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
	14(4), 539-47 * Abstract *	8,16,40	
P,Y	CHEMICAL ABSTRACTS, vol. 102, no. 15 15th April 1985, page 283, abstract no. 128005x, Columbus, Ohio, US; Ch.K. WAT et al.: "Photosensitizer- protein conjugates:potential use as photoimmunotherapeutc agents", & PROG.CLIN.BIOL.RES. 1984, 170 (Porphyrin localization treat tumors), 351-9		
	* Abstract *	1-7,9- 15,17-	TECHNICAL FIELDS SEARCHED (Int. Cl.4)
P,Y	CHEMICAL ABSTRACTS, vol. 103, no. 15, 14th October 1985, page 558, abstract 121395m, Columbus, Ohio, US; D. MEW et al.: "Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation", & CANCER RES. 1985, 45(9), 4380-6		
	* Abstract *	1-40	
A	THE JOURNAL OF IMMUNOLOGY, vol. 125, no. 3, September 1980, page 1201, Williams & Wilkins Co. US; G.W. PHILPOTT et al.: "Selective binding and cytotoxicity of rat basophilic leukemia cells (RBL-1) with immunoglobulin E-biotin and avidin-glucose oxidase conjugates"		
Y	CHEMICAL ABSTRACTS, vol. 89,no. 13, 25th September 1978, page 29, abstract no. 110773z Columbus, Ohio, US; & JP - A - 77 141 882 (E. HASEGAWA et al.) 26-1-1977		
	* Abstract *	42	

## PARTIAL EUROPEAN SEARCH REPORT

0 1,7,5,6,1,7 EP 85 40 1776

	DOCUMENTS CONSIDERED TO BE RELEVANT	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)	
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
А	CHEMICAL ABSTRACTS, vol. 97, no. 7, 16th August 1982, page 224, abstract no. 51193a Columbus, Ohio, US; H. SAKURAI et al.: "Growth inhibition and photoxidative toxicity in the housefly. Musca domestica L.caused by xanthene dye in larval growth medium and after injection" & ENVIRON.ENTOMOL. 1982, 11(2), 467-70		
	* Abstract *	43	
P,Y	CANCER RESEARCH, vol. 45, September 1985, pages 4380-4386 D. MEW et al.: "Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation"		TECHNICAL FIELDS SEARCHED (Int. Cl.4)
-	* Whole document *	1-7, 9-15, 17-39	
P,A	CHEMICAL ABSTRACTS, vol. 103, no. 5, 5th August 1985, page 491, abstract no. 37259n Columbus, Ohio, US; R. OCAMPO et al.: "Identification of polar porphyrins in oil shale" & J.CHEM.SOC.CHEM.COMMUN. 1985, (4), 198-200		•
	* Abstract *	42	
	•		
•			